There is growing interest in markers that can be used to identify which patients are most likely to benefit from a treatment. For example, the Gail breast cancer risk prediction model may be useful for identifying a subset of older women for whom the benefit of tamoxifen for breast cancer prevention is likely to outweigh the harm. Two general classes of approaches to evaluating treatment selection markers have been developed. The first uses data on a cohort of untreated subjects to develop a risk prediction model, such as the Gail model, which is used to identify a high-risk subset of subjects. This model is paired with a measure of treatment effect to assess the impact of identifying and treating the high-risk subset. The second approach uses data from a randomized trial to model the treatment effect on a composite outcome that includes all effects of treatment (positive and negative). The treatment effect model is used to identify a subset of subjects with positive treatment effects and to assess the impact of identifying and treating this subset. We describe a framework that includes both existing approaches as special cases. In doing so, we review the existing approaches, clarify their underlying assumptions, and facilitate the evaluation of markers under less restrictive assumptions.
There is growing interest in markers that can be used to identify which patients are most likely to benefit from a treatment. For example, the Gail breast cancer risk prediction model may be useful for identifying a subset of older women for whom the benefit of tamoxifen for breast cancer prevention is likely to outweigh the harm. Two general classes of approaches to evaluating treatment selection markers have been developed. The first uses data on a cohort of untreated subjects to develop a risk prediction model, such as the Gail model, which is used to identify a high-risk subset of subjects. This model is paired with a measure of treatment effect to assess the impact of identifying and treating the high-risk subset. The second approach uses data from a randomized trial to model the treatment effect on a composite outcome that includes all effects of treatment (positive and negative). The treatment effect model is used to identify a subset of subjects with positive treatment effects and to assess the impact of identifying and treating this subset. We describe a framework that includes both existing approaches as special cases. In doing so, we review the existing approaches, clarify their underlying assumptions, and facilitate the evaluation of markers under less restrictive assumptions. Key words: clinical prediction rules; risk stratification; decision analysis. (Med Decis Making 2014; 34:159-167) M arkers that can be used to identify which patients are likely to benefit from a treatment are highly sought after in many clinical contexts. This is especially true in settings in which the treatment has varying efficacy and is associated with substantial toxicity, for example, cancer therapies. In these contexts, the provision of treatment is warranted only if the magnitude of the benefit outweighs the potential harm. Treatment selection markers, sometimes called predictive 1 or prescriptive 2 markers, predict the magnitude of the treatment effect and can therefore be used to recommend treatment to individuals who are most likely to benefit from it and to avoid treatment in those not likely to benefit. 1, [3] [4] [5] Suppose that treatment reduces the risk of a bad outcome, which we call the treatment-targeted outcome, but it also has negative effects manifested by secondary outcomes or events. Two general classes of statistical approaches to evaluating treatment selection markers have been developed. The first uses the marker to model risk of the targeted event in the absence of the treatment intended to prevent this event. This risk prediction model is used to identify a high-risk subset of patients who have the most potential to benefit from treatment (see . For evaluating the impact of identifying and treating the high-risk subset, the risk model is paired with a measure of treatment effect. Typically it is assumed that treatment yields a constant reduction in risk of the targeted event. The second approach uses data from a randomized controlled trial (RCT) comparing treatment options to model the association between the marker and treatment effect on a composite outcome variable that incorporates the targeted and secondary events. This model is then used to identify a subset of patients with positive treatment effects who can be recommended treatment. 5, [11] [12] [13] [14] This paper reviews both existing approaches to marker evaluation and develops a framework that encapsulates them both. The work is intended to bridge the gap that exists between researchers and methods focused on risk modeling versus those aimed at treatment effect modeling. Additionally, it clarifies the assumptions underlying the 2 approaches and facilitates the evaluation of markers under less restrictive assumptions.
The methods described herein follow a decisiontheoretic approach to marker evaluation in order to address the overarching question: What is the benefit of using the marker to select patient treatment instead of using the default treatment strategy of either treating or not treating all patients? This approach requires specifying values for occurrences such as the targeted event, secondary events, treatment provision, and marker measurement. While specifying these utilities is difficult in practice, we demonstrate that the existing approaches to marker evaluation that do not explicitly specify these utilities are implicitly making assumptions about their values. Specifically, we show that the existing approaches to marker evaluation are special cases of the more general framework, under particular choices for the utilities.
After defining the setting of interest, we overview the 2 existing classes of approaches to marker evaluation, risk modeling and treatment effect modeling. In what follows we develop and illustrate the more general framework and show that the existing approaches are special cases. For illustration, we use the clinical context from a paper by Gail, 7 in which the goal is to identify a subset of older women who can be recommended tamoxifen for breast cancer prevention on the basis of breast cancer risk. Mathematical details are provided in the online appendix.
METHODS
Consider the simple setting in which the task is to decide between 2 treatment options, referred to as ''treatment'' (T 5 1) and ''no treatment'' (T 5 0). We assume that in the population as a whole the harm of treatment outweighs the benefit, so that the default treatment strategy is to not treat patients. If the opposite scenario holds where the default treatment strategy is to treat all patients, this can be accommodated with a simple interchanging of treatment labels. The binary event targeted by treatment is denoted by D, where D 5 1 indicates the targeted event and D 5 0 indicates no targeted event. For example, in a prevention setting D might be an indicator of incident breast cancer, or in a prognostic setting it might represent breast cancer recurrence. The conceptual approach applies generally to continuous, count, or time-toevent outcomes. The candidate marker, denoted by Y, may be a single measurement or a score that combines the results of multiple measurements.
RESULTS

Risk Modeling to Identify High-Risk Subjects
The first approach to evaluating a marker for treatment selection entails modeling the risk of the targeted event in the absence of preventive treatment as a function of the marker, that is, PðD 5 1jT 5 0;YÞ (see . This risk prediction model is used to identify a subset of subjects at high risk of the targeted event, the basic idea being that highrisk subjects have the most potential to benefit from treatment. 6 To estimate the risk model, one requires data on a cohort of untreated subjects (T 5 0) who have marker Y measured at baseline and are followed for targeted event D.
A classic result from decision theory specifies the optimal rule for identifying high-risk subjects who are recommended treatment. If C FP quantifies the burden associated with treatment for a subject who would not have the targeted event absent treatment (the burden of a false positive) and B TP is the benefit of treatment for a subject who would have the targeted event absent treatment (the benefit of a true positive), the optimal rule is to recommend treatment to subjects for whom Risk 0 ðYÞ 5 PðD 5 1jT 5 0;YÞ is above r 0 5 C FP C FP þB TP . 15 Intuitively, the higher the burden of a false positive relative to the benefit of a true positive, the higher a subject's risk needs to be to warrant treatment. The utilities C FP and B TP are entirely general and may take into account probabilities of targeted or secondary events, quality of life measures, or monetary costs. Their values rely on assumptions regarding the impact of treatment on targeted and secondary events, as will be illustrated below.
The population expected benefit of the marker quantifies the impact of using the marker to identify and treat the high-risk subset. This is defined as the difference in the expected benefit of marker-based treatment minus the expected benefit of the default strategy of not treating any subjects. If Y þ 5 1 denotes marker positivity, where Y þ 5 1 implies that treatment is recommended and Y þ 5 0 implies no treatment, TPRðY þ Þ 5 PðY þ 5 1jD 5 1;T 5 0Þ is the proportion of subjects who would develop the targeted event absent treatment who are classified as positive (the true-positive rate), and FPRðY þ Þ 5 PðY þ 5 1jD 5 0;T 5 0Þ is proportion of subjects who would not develop the targeted event absent treatment who are positive (the false-positive rate), the expected benefit of the marker is given by
The optimal marker positivity rule for an individual subject, namely Y þ 5 1 if Risk 0 ðYÞ.r 0 , maximizes the population expected benefit given in Equation 1.
Gail's Implementation
Gail 7 is a key example of this approach that we consider in detail. He evaluates the utility of the Gail breast cancer risk prediction model for identifying a subset of healthy older white women (aged 50-59) who can be recommended tamoxifen for breast cancer prevention. In this context, D is an indicator of developing breast cancer over a 1-year period, T is an indicator of tamoxifen provision, and Y is the Gail risk of breast cancer over the next year given age at menarche, age at first live birth, number of previous breast biopsy examinations, and the total number of first-degree relatives with breast cancer. 16 Gail identifies the utilities C FP and B TP using the following approach (see the online appendix for details). A subject who would not develop breast cancer in the absence of tamoxifen suffers the burden of treatment, which Gail measures by the impact of tamoxifen on the risk of 4 secondary (side effect) events, namely, hip fracture, endometrial cancer, stroke, and pulmonary embolism. Specifically, if O j are indicators of these secondary events, j 5 1;2;3;4, and RR O j denotes the relative risk of event O j associated with tamoxifen use, C FP 5 P 4
PðO j 5 1jT 5 0ÞðRR O j À 1Þ, assuming that the 4 secondary events are mutually exclusive. However, a subject who would develop breast cancer in the absence of tamoxifen benefits from treatment according to her reduction in risk of breast cancer less the burden of tamoxifen, that is,
where RR D is the decrease in risk of breast cancer associated with tamoxifen. Note here the assumption that the effects of tamoxifen are constant on a relative risk scale: That is, RR D and RR O j do not vary in Y.
Given these values for C FP and B TP , the optimal rule is to recommend tamoxifen to women whose breast cancer risks are above r 0 5 P 4
Using rates of breast cancer and secondary events obtained from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program and medical records studies, as well as relative risks associated with tamoxifen from randomized trials, Gail obtains the values C FP 5101:6ð0:55À1Þþ81:4ð4:01À1Þþ110:0ð1:59À1Þ þ50:0ð3:01À1Þ310 À5 53:65310 À3 and B TP 51À0:51 ÀC FP 50:486, which yields an optimal risk threshold of r 0 57:44310 À3 , suggesting that women with 1year breast cancer risk above this value should be recommended tamoxifen. (There appears to be a small typographical error in Gail 7 where this value is given as 7:74310 À3 .) Note that r 0 57:44310 À3 represents 3 times the population average risk of breast cancer in the absence of tamoxifen, which is 2:47310 À3 . This relatively low risk threshold for recommending tamoxifen is a consequence of the small size of the assumed burden of tamoxifen, C FP , relative to its benefit, B TP .
Since Gail uses adverse events (breast cancer or secondary) as his unit of currency, his expected benefit can be interpreted as the reduction in the population event rate under marker-based treatment. Using the distribution of Gail risk factors estimated from the 2000 National Health Interview Survey as described in Reference 17), Gail calculates the population expected benefit of using the Gail risk model to identify and treat a high-risk subset as 1:4 3 10 À5 (see online appendix). Considering that 589:6 3 10 À5 is the composite rate of events if tamoxifen is not provided to any women, this represents a very modest 0.2% reduction in the composite event rate (1:4=589:6 5 0:002). Gail helpfully contrasts this with the reduction in the composite event rate that would be achieved using a perfect risk prediction model that puts all women who would develop breast cancer absent tamoxifen at Risk 0 ðYÞ 5 1 and assigns Risk 0 ðYÞ 5 0 to those who would not. According to (1) , this perfect risk prediction model would have an expected benefit of B TP PðD 5 1jT 5 0Þ 5 119:9 3 10 À5 , which represents a much larger 20% reduction in the population composite event rate. Therefore, the low expected benefit of the Gail risk model is a consequence of its limited predictive capacity. 18 Gail's approach makes several key assumptions, as shown in detail in the online appendix. It relies on the assumption that the burden and benefit of tamoxifen are captured by its effect on risk of breast cancer, hip fracture, endometrial cancer, stroke, and pulmonary embolism; that the burden of breast cancer is equal to the burden of the 4 other event types; that this burden is constant across subjects, not varying with patient characteristics or breast cancer risk factors; that the impact of tamoxifen is a constant increase or decrease in risk of each event type on the multiplicative scale; that tamoxifen can cause the secondary events but not breast cancer; and that knowing a woman's breast cancer status tells us nothing about her likelihood of experiencing a secondary event. Other authors (e.g., Gail and others 19 and Baker and Kramer 20 ) have expanded on this framework to allow for unequal weighting of the secondary event types. Many of the remaining assumptions can be relaxed using the approach discussed next, and all can be relaxed in the framework that follows.
Treatment Effect Modeling to Identify Subjects with Positive Treatment Effects
The second approach to evaluating a marker for treatment selection entails modeling the absolute treatment effect on a composite outcome, D Ã , that incorporates both the treatment-targeted and secondary outcome events. The treatment effect on the composite outcome is modeled as a function of marker value, that is, PðD Ã 5 1jT 5 0;YÞ À PðD Ã 5 1j T 5 1;YÞ[DðYÞ, in order to identify a subset of subjects with positive treatment effects. 5, [11] [12] [13] [14] For estimation, ideally one would have data from an RCT comparing T 5 0 to T 5 1 where the marker, Y, is measured at baseline on all or a design-selected sample of trial participants.
For an individual subject with marker value Y, the optimal rule is to treat if the absolute treatment effect is positive, that is, Y þ 5 1 if DðYÞ.0. The population benefit of using the marker to assign treatment is the decrease in the composite event rate, relative to that under the default strategy of no treatment: This approach assumes that the outcome, D Ã , is defined in such a way as to capture all beneficial and adverse effects of treatment, so that any positive treatment effect, no matter how small, warrants treatment. For example, in the breast cancer prevention context, the composite event D Ã would be an indicator of any adverse event: breast cancer, hip fracture, endometrial cancer, stroke, or pulmonary embolism over a 1-year period. More generally, a continuous D Ã could be an importance-weighted sum of the various adverse events. Given data from an RCT comparing tamoxifen to placebo where Gail risk factors were measured at baseline, the effect of tamoxifen on the absolute risk of this composite event could be modeled as a function of Gail risk factors, for example using a logistic regression model for PðD Ã 5 1jT;YÞ and including T, Y, and T-by-Y interaction as predictors. This model could then be used to identify a subset of women whose risk of D Ã is smaller with the provision of tamoxifen than without.
This approach avoids some of the assumptions implicit in Gail's approach, such as the assumptions that there are event-type-specific relative risks for tamoxifen that are constant in Y, that tamoxifen does not cause breast cancer, and that there is statistical independence between breast cancer and secondary events. However, using this approach requires that the outcome, D Ã , be defined so as to capture all the burdens and benefits of tamoxifen and to capture them equally well for all subjects. A more flexible approach is described next.
Framework for Marker Evaluation
A more general approach to evaluating a treatment selection marker is described in this section; the existing approaches are shown below to be special cases. The following utilities are involved: C D ðYÞ is the burden of the targeted event in the absence of treatment (D 5 1;T 5 0). C T ðYÞ is the burden of treatment in the absence of the targeted event (D 5 0;T 5 1). C DT ðYÞ 5 C D ðYÞ þ C T ðYÞ þ C þþ ðYÞ is the burden of having both the treatment and the targeted event (D 5 1;T 5 1). C M is the burden of measuring the marker.
The burden of no treatment and no targeted event (D 5 0;T 5 0) is set to zero, which means that all other burdens are defined over and above this. In the breast cancer example, C T ðYÞ is the burden of tamoxifen for someone who does not develop breast cancer, C D ðYÞ is the burden of breast cancer for someone who does not suffer preventive treatment with tamoxifen, and C DT ðYÞ is the burden of having preventive treatment and nevertheless developing breast cancer. The utilities C D ðYÞ;C T ðYÞ, and C DT ðYÞ are entirely general and could represent, for example, increases in morbidity and mortality in the D 5 1;T 5 0; D 5 0;T 5 1; and D 5 1;T 5 1 subgroups relative to the D 5 0;T 5 0 group.
The utilities are allowed to depend on the marker, Y, to accommodate the fact that the burdens associated with the targeted event and with treatment may differ among patients and that this could be related to the marker. For example, age is a strong risk factor for the non-breast cancer events, which means that the burden of tamoxifen, as measured by the increase in risk of these events on a relative risk scale, is larger for older versus younger women. The burden of breast cancer, which Gail sets to C D 5 1, may also take different values depending on person's age; a breast cancer diagnosis will have a larger effect on a younger woman because of its effects on family, life years, and so on. For this reason, Gail 7 focused on a restricted age range (50-59 years). However, to calculate the population benefit of Y, these age-specific burdens would need to be acknowledged. Other markers, such as C-reactive protein, may predict risk of multiple event types such as breast cancer and pulmonary embolism.
Gail's approach simply added together the burden of breast cancer and of tamoxifen use; however, in general these may not be additive. The utility C þþ ðYÞ allows the burden of the targeted event and treatment together to be different from the burden of the event plus the burden of treatment. This is useful in contexts in which the burden of treatment differs depending on whether a subject has the targeted event. For example, the toxicity of preventive treatment might be more severe if the subject develops a chronic disease. Alternatively, there may be a different burden of the targeted event when treatment is provided. Perhaps the manifestation of disease (e.g., its stage or severity) is different under treatment. In the example below, we argue that the burden of breast cancer should be higher in the context of tamoxifen use, since it may be harder to treat.
This approach also factors in the burden of measuring the marker on all subjects, C M . This burden is negligible for the Gail risk factors, all of which can be obtained by patient questionnaire. However, for biomarkers such as gene expression or genotype, or markers measured using imaging technology, the financial cost can be substantial. There may be additional burden if obtaining a biological specimen for testing is invasive.
Consider the treatment rule for a subject with marker Y. As shown in the online appendix, this subject should be treated if the treatment effect exceeds the burden of treatment, that is, Y þ 5 1 if D s ðYÞ 5 PðD 5 1jT 5 0;YÞC D ðYÞ À PðD 5 1jT 5 1;YÞ ðC D ðYÞ þ C þþ ðYÞÞ . C T ðYÞ.
The corresponding population expected benefit of the marker, given by the difference in the expected burden associated with treating no subjects versus treating those with Y þ 5 1, is
where EðÞ denotes an average taken over the population. Intuitively, the expected benefit is the net benefit of treatment among those who are marker-positive times the proportion who are marker-positive, offset by the burden of measuring the marker on all subjects. The optimal treatment rule Y þ 5 1 if D s ðYÞ.C T ðYÞ maximizes the expected benefit in (3).
Illustration
We illustrate the approach in the breast cancer prevention context, where Y may be useful for identifying women who benefit from tamoxifen for breast cancer prevention. Here C D is the burden associated with a breast cancer diagnosis in the next year for a 50-to 59-year-old white woman who is not taking tamoxifen. We set C D 5 1 as in Gail 7 so that all other events are evaluated relative to this. The burden of taking tamoxifen twice daily for a 1-year period, without a breast cancer diagnosis during that time period, is quantified by considering the likelihood of it causing endometrial cancer, stroke, and pulmonary embolism in addition to the more frequent but less onerous side effects that include nausea, hot flashes, cataracts, sexual problems, vaginal discharge, and irregular periods; these risks are offset somewhat by a decrease in the risk of hip fracture. 19, [21] [22] [23] [24] [25] The difficulty lies in putting all of these potential side events on the scale of a breast cancer diagnosis. Yet, this is the task faced by each woman who has to decide whether the benefits of tamoxifen outweigh the harms for her. We use our personal judgment, taking into account both the increased risk of side effects under tamoxifen and the relative severity of each side effect, to assign the value C T 5 0:1. In other words, we assume that the burden of tamoxifen is 10% of the burden of breast cancer, or that the harm of treating 10 women with tamoxifen is equivalent to 1 breast cancer event. The burden of taking tamoxifen for 1 year and also being diagnosed with breast cancer is then at least C D þ C T 5 1:1. We increase this burden by C þþ 5 0:5, to allow for the fact that tamoxifen may only prevent estrogen receptor (ER)positive breast cancer, so that breast cancer diagnosed in the context of tamoxifen use is more likely to be ER-negative and therefore generally harder to treat. [26] [27] [28] That is, we assume that tamoxifen reduces the risk of breast cancer but that breast cancer diagnosed following tamoxifen provision may be harder to treat. Stage of breast cancer diagnosis is another important consideration here; if breast cancer that develops in the context of tamoxifen use is likely to be detected at an earlier or later stage, this should be taken into account in setting C þþ . We know of no evidence of such an effect of tamoxifen.
We applied these utilities to the evaluation of 2 hypothetical markers, the first of which has the same performance as the Gail risk model (see Figure 1) . Each marker follows a standard normal distribution and satisfies logit PðD 5 1jT;YÞ 5 a 0 þ a 1 Tþ a 2 Y þ a 3 Y 2 þ a 4 TY þ a 5 TY 2 , where the coefficients are constrained to yield the population-level annual breast cancer rates of 125:8 3 10 À5 and 246:6 3 10 À5 with and without tamoxifen as in Gail 7 . Marker Y 1 , which has an expected benefit of 1:4 3 10 À5 , the same as the Gail risk model using Gail's C D 5 1, C T 5 3:65 3 10 À3 , and C þþ 5 0, has virtually zero expected benefit with our choice of C D 5 1, C T 5 0:1, and C þþ 5 0:5, since no subjects have scaled absolute treatment effects, D s ðY 1 Þ 5 PðD 5 1jT 5 0; Y 1 Þð1Þ À PðD 5 1jT 5 1;Y 1 Þð1:5Þ, that are above the burden of tamoxifen, C T 5 0:1 ( Figure 1A) . In contrast, marker Y 2 has a strong statistical interaction with T in the logistic model and therefore much greater expected benefit. As shown in Figure 1B , there is substantial variation in D s ðY 2 Þ as a function of Y 2 , with some subjects having large positive or negative scaled absolute treatment effects. The expected benefit of tamoxifen among Y 2 marker-positives is 0.18, and 0.4% of subjects are marker-positive. The associated expected benefit of Y 2 is therefore 6.84 3 10 À4 , which corresponds to a substantial 28% reduction in burden from that associated with the default treatment strategy of not treating any women with tamoxifen.
Special Cases
Gail's approach is a special case of this approach to marker evaluation. He uses breast cancer events as the units of burden (C D 5 1), defines the burden of tamoxifen absent breast cancer to be C T 5 C FP 5 P 4 j 5 1 PðO j 5 1jT 5 0ÞðRR O j À 1Þ, assumes that the burdens of breast cancer and tamoxifen are additive (C þþ 5 0), and sets the burden of measuring the Gail risk factors to zero (C M 5 0). Furthermore, he specifies PðD 5 1jT 5 1;YÞ 5 Risk 0 ðYÞRR D , which implies that D s ðYÞ 5 PðD 5 1jT 5 0;YÞ À PðD 5 1j T 5 1;YÞ 5 Risk 0 ðYÞð1 À RR D Þ, and sets B FP 5 ð1À RR D Þ À C FP , which implies that C FP þ B TP 5 1 ÀRR D . Therefore, the optimal rule to treat if D s ðYÞ.C T ðYÞ reduces to treating high-risk subjects who satisfy Risk 0 ðYÞ. C FP ð1ÀRR D Þ 5 C FP C FP þB TP . The formulation of the expected benefit of Y in (3) also reduces to Gail's formulation (1) , as shown in the online appendix.
Observe that under Gail's approach, even though the relative risk RR D is constant in Y, the absolute treatment effect DðYÞ 5 PðD 5 1jT 5 0;YÞÀ PðD 5 1j T 5 1;YÞ 5 Risk 0 ðYÞð1 À RR D Þ does vary in Y. Therefore, a constant treatment effect on the relative risk scale induces an absolute treatment effect that varies in Y, that is, a marker-by-treatment interaction. Many authors have pointed out that such an interaction is necessary for a marker to have value for treatment selection. 1, 3, 5 As seen in Figure 1 , markers that interact with treatment on an odds ratio or relative risk scale have much greater potential to provide benefit for treatment selection.
Other methods for evaluating treatment selection markers are also special cases of this approach. Vickers and others 29 proposed a form for the expected benefit of a treatment selection marker that is a special case of this formulation under the restrictions C D ðYÞ 5 C D , C T ðYÞ 5 C T , and C þþ ðYÞ 5 C M 5 0 (see online appendix). The population event rate measure proposed in References 5 and 11-14 assumes C D ðYÞ 5 1 and C T ðYÞ 5 C þþ ðYÞ 5 C M 5 0. As mentioned above, this is justified when the outcome D Ã captures all of the effects (both positive and negative) of treatment.
DISCUSSION
This paper reviews Gail's 7 approach to evaluating a marker for treatment selection and shows that it is a special case of a more general approach that facilitates marker evaluation under less restrictive assumptions. Other existing approaches, including that which models the association between marker and treatment effect on a composite outcome in order to identify and treat subjects with positive treatment effects, 5, [11] [12] [13] [14] are also special cases. Our framework helps to clarify the relationships among the various approaches and to elucidate their underlying assumptions.
In related work, Vickers and Elkin 30 introduced the ''decision curve'' for evaluating the expected benefit of a marker for predicting risk of the targeted event. The relative utility curve of Baker and others 31 is a scaled decision curve that captures the fraction of expected benefit relative to that of a perfect marker.
These approaches fall into the class we call ''risk modeling'' and therefore depend on simplifying assumptions about the utilities, similar to those assumptions used in Gail's 7 approach. However, the approaches are useful more broadly in that they exemplify the notion of sensitivity analysis, whereby the expected benefit of the marker is examined over a range of possible values for the utilities. A sensitivity analysis would be useful for assessing the expected benefit in Equation 3 as a function of the set of utilities.
A number of additional papers have proposed statistical methods for treatment selection markers that we have not discussed. Many describe approaches to estimating the treatment effect on targeted event as a function of the marker (e.g., . However, these papers do not include measures of the population benefit of using the marker to select treatment. Others (e.g., References 20 and 36) address a different question of the benefit of treatment in the marker-positive subgroup. We note that the expected benefit of treatment among marker-positives, multiplied by the proportion marker-positive and less the cost of measuring the marker, is the expected benefit of the marker given in Equation 3. Moreover, examining the expected benefit among markerpositives separately from that among markernegatives is a way to allow for utilities to depend on marker (positivity). Figure 1 Marker-specific 1-year risk of breast cancer with and without tamoxifen (left) and cumulative distribution of the scaled absolute tamoxifen effect, D s ðYÞ 5 PðD 5 1jT 5 0;YÞð1Þ À PðD 5 1jT 5 1;YÞð1:5Þ, (right) for 2 hypothetical markers for identifying women who benefit from tamoxifen for the prevention of breast cancer. (A) Marker Y 1 has the same performance as the Gail breast cancer risk prediction model; (B) Marker Y 2 is a much stronger treatment selection marker. In the right panel, a dotted vertical line indicates the optimal marker positivity threshold where the scaled absolute treatment effect equals the burden of providing tamoxifen, that is, D s ðYÞ 5 C T 5 0:1; this value is off the plot for marker Y 1 . Subjects with scaled treatment effects above this threshold are recommended tamoxifen for breast cancer prevention.
The approach to marker evaluation that we describe ideally uses data from a randomized trial comparing the 2 treatment options, where the marker is measured at baseline on all trial participants or a random subset of them. Absent these data, assumptions have to be made as to how the treatment effect varies as a function of marker value. Gail's approach 7 is one such example where it is assumed that the treatment effects on the targeted event and on secondary events are constant on the relative risk scale.
The scale of the model relating marker to outcome is important. A marker that does not interact with treatment on a relative risk scale does have an interaction with treatment on the absolute scale and therefore can have some value for treatment selection. Yet, how useful such a marker can be depends on the clinical context, specifically on the underlying risk of the targeted events and on the net benefit of treatment. Markers that yield absolute treatment effects with substantial variation are associated with much greater potential benefit.
If the burden of the targeted or secondary events depends on a particular variable (e.g., the clinical setting or a subject characteristic), it follows that the optimal treatment rule is a function of that variable. This implies that any variables that affect the utilities should be considered as markers and should be included as predictors when modeling the risk of the targeted event. A corollary of this is that if the utilities depend on a variable, ignoring this and assuming that they are constant will yield a less than optimal expected benefit of marker-based treatment.
Obtaining utilities is a fundamental requirement for a decision-theoretic evaluation of marker performance. An implication of this work is that the data required to calculate these utilities should be routinely collected in randomized clinical trials evaluating treatment efficacy. For example, secondary events associated with treatment and potentially medical cost data as well should be collected for all trial participants or a random sample of them. Participant questionnaires might also be used to ascertain perceived burden associated with the targeted and secondary events. The utilities C T ðYÞ;C D ðYÞ, and C DT ðYÞ represent the average burden, as measured by 1 or more of these instruments, in the In practice, a confidence interval should be provided along with the point estimate for the expected benefit of the marker in order to convey the degree of uncertainty. Estimation and inference methods are discussed in the online appendix. If the marker of interest is a score combining multiple markers, to avoid overfitting the score should be obtained using a separate dataset from that used to assess the expected benefit; see Reference 37 for a summary of methods for accomplishing this.
